Clinical Trial Start-up and Site Initiation process from the CRA perspective – The number 1 hot topic in pandemic times
Clinical Trial Workshop with Ken:
Meet Ken Boudreault, Sr.CRA on Nov. 21, 2020
CRA-School is proud to present the next workshop from
our Clinical Trial Monitoring series on the hot topic
Clinical Trial Start-up & Site Initiation: A CRA perspective
The Study Start-up involves all the activities that take place from the first contact between a sponsor and a potential investigator to the moment that the study team is ready to screen and enroll subjects.
Today, with plenty of new clinical trials generated by the pandemic, fast and efficient study start-up and site activation is of extreme importance
Ken Boudreault (Senior CRA), will host this workshop, focusing on the responsibilities of the CRA during the initial phases of a clinical trial: selecting the site, study feasibility assessment, Pre-study Site Qualification Visit, Site Initiation Visit, Challenges in interacting with key site personnel
When: Saturday, November 21st, from 9 am till noon.
Where: worldwide, by Zoom
Who should attend?
Anyone interested in becoming a CRA and looking for insight from an experienced professional, or any current CRA, who wishes to share tips and hear other points of view from a seasoned colleague.
This workshop is of particular interest also for researchers and research assistants, who intend to start a clinical study or want to participate in industry-financed clinical trials.
Why should you attend?
Learning from an experienced professional and asking him questions face-to-face is the best way to understand how to get ahead and avoid errors, either in the day-to-day functions as a CRA, or more generally, in your career path.
A certificate of attendance for professional development will be available to every participant who completes the workshop.
Fees
Regular price: $30,00+tx
Early birds: $25,00+tx (until November 7)
CRA School students: $25,00+tx
See more career opportunities in the clinical trials industry here:
